Medizinische Klinik, Abteilung für Innere Medizin III, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, Heidelberg, Germany.
Clin Res Cardiol. 2011 Mar;100(3):209-15. doi: 10.1007/s00392-010-0230-y. Epub 2010 Sep 18.
We sought to determine the performance of the new high sensitivity cardiac troponin T assay (TnThs) for early diagnosis of myocardial infarction in patients with suspected acute coronary syndrome (ACS) and compare it with the fourth generation cTnT assay, myoglobin and heart-type fatty acid binding protein (h-FABP).
Ninety-four patients with diagnosis of suspected ACS without ST-segment elevation admitted to our chest pain unit were included. Patients were divided according to time from onset of symptoms to presentation into an early presenter group (<4 h) and a late presenter group (≥4 h). A median of six samples (range 2-8) were available per patient. The diagnostic performance of TnThs was assessed using ROC analysis. Areas under the curve (AUC) of baseline and follow-up results of TnThs, cTnT, myoglobin, and h-FABP were compared using c statistics.
The TnThs assay allows an excellent prediction of non-ST-segment elevation myocardial infarction (non-STEMI) at presentation, particularly among late presenters. A follow-up sample improves diagnostic performance in a time-dependent manner. The AUC of TnThs was superior to cTnT at all time points. The performance of TnThs was at least as good as myoglobin and h-FABP at presentation and during follow-up.
A baseline sample of TnThs allows an earlier prediction of non-STEMI than the less sensitive and precise fourth generation cTnT assay. Probably, this excellent performance of TnThs at baseline and follow-up could obviate the need for other early markers of necrosis in future.
我们旨在确定新的高敏心肌肌钙蛋白 T 检测(TnThs)在疑似急性冠状动脉综合征(ACS)患者中的早期诊断性能,并将其与第四代 cTnT 检测、肌红蛋白和心脏型脂肪酸结合蛋白(h-FABP)进行比较。
纳入 94 例诊断为疑似 ACS 且无 ST 段抬高的患者,这些患者被分为早期表现组(<4 小时)和晚期表现组(≥4 小时)。每位患者的中位数有 6 个样本(范围 2-8 个)。采用 ROC 分析评估 TnThs 的诊断性能。使用 C 统计量比较 TnThs、cTnT、肌红蛋白和 h-FABP 的基线和随访结果的曲线下面积(AUC)。
TnThs 检测可极好地预测就诊时的非 ST 段抬高型心肌梗死(NSTEMI),特别是在晚期表现者中。随时间推移进行随访样本可提高诊断性能。TnThs 的 AUC 在所有时间点均优于 cTnT。TnThs 的性能在就诊时和随访期间均至少与肌红蛋白和 h-FABP 一样好。
TnThs 的基线样本可比敏感度和精密度较差的第四代 cTnT 检测更早地预测 NSTEMI。可能 TnThs 在基线和随访时的优异性能未来可省去对其他早期坏死标志物的需求。